(Q34430377)

English

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 August 2017

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs (English)

1 reference

Europe PubMed Central

2 August 2017

hypercholesterolemia

0 references

familial hypercholesterolemia

1 reference

based on heuristic

inferred from title

object named as

Sandy Elbitar

2

0 references

object named as

Youmna Ghaleb

4

0 references

Jean-Pierre Rabès

object named as

Jean-Pierre Rabès

7

0 references

Mathilde Varret

object named as

Mathilde Varret

8

0 references

Catherine Boileau

object named as

Catherine Boileau

9

0 references

Marianne Abifadel

1

object named as

Marianne Abifadel

1 reference

Europe PubMed Central

2 August 2017

Petra El Khoury

3

object named as

Petra El Khoury

1 reference

Europe PubMed Central

2 August 2017

author name string

Mélody Chémaly

5

1 reference

Europe PubMed Central

2 August 2017

Marie-Line Moussalli

6

1 reference

Europe PubMed Central

2 August 2017

publication date

1 September 2014

1 reference

Europe PubMed Central

2 August 2017

Current Atherosclerosis Reports

1 reference

Europe PubMed Central

2 August 2017

16

1 reference

Europe PubMed Central

2 August 2017

9

1 reference

Europe PubMed Central

2 August 2017

439

1 reference

Europe PubMed Central

2 August 2017

https://scigraph.springernature.com/pub.10.1007/s11883-014-0439-8

0 references

Familial defective apolipoprotein B-100: low density lipoproteins with abnormal receptor binding

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A third major locus for autosomal dominant hypercholesterolemia maps to 1p34.1-p32

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Precursor convertases in the secretory pathway, cytosol and extracellular milieu

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Functional characterization of Narc 1, a novel proteinase related to proteinase K

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Catalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cells

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The crystal structure of PCSK9: a regulator of plasma LDL-cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Molecular basis for LDL receptor recognition by PCSK9

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The cellular trafficking of the secretory proprotein convertase PCSK9 and its dependence on the LDLR

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

After the LDL receptor and apolipoprotein B, autosomal dominant hypercholesterolemia reveals its third protagonist: PCSK9

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Mutations in the PCSK9 gene in Norwegian subjects with autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Familial hypercholesterolaemia in Portugal.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Characterization of novel mutations in the catalytic domain of the PCSK9 gene

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Identification and characterization of two non-secreted PCSK9 mutants associated with familial hypercholesterolemia in cohorts from New Zealand and South Africa

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of mutations in the PCSK9 gene on the cell surface LDL receptors

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Healthy individuals carrying the PCSK9 p.R46L variant and familial hypercholesterolemia patients carrying PCSK9 p.D374Y exhibit lower plasma concentrations of PCSK9.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Molecular characterization of loss-of-function mutations in PCSK9 and identification of a compound heterozygote

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Genetic variation at the PCSK9 locus moderately lowers low-density lipoprotein cholesterol levels, but does not significantly lower vascular disease risk in an elderly population

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker for plasma low-density lipoprotein cholesterol levels and severity of coronary atherosclerosis

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effects of PCSK9 variants on common carotid artery intima media thickness and relation to ApoE alleles.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The E670G SNP in the PCSK9 gene is associated with polygenic hypercholesterolemia in men but not in women

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study).

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A PCSK9 missense variant associated with a reduced risk of early-onset myocardial infarction

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Variation in PCSK9, low LDL cholesterol, and risk of peripheral arterial disease

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Common and Low-Frequency Genetic Variants in the PCSK9 Locus Influence Circulating PCSK9 Levels

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Sequence variation in proprotein convertase subtilisin/kexin type 9 serine protease gene, low LDL cholesterol, and cancer incidence

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Biomedicine. Lowering LDL--not only how low, but how long?

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A PCSK9 variant and familial combined hyperlipidaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Increased secretion of lipoproteins in transgenic mice expressing human D374Y PCSK9 under physiological genetic control.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Proprotein convertase subtilisin/kexin type 9 interacts with apolipoprotein B and prevents its intracellular degradation, irrespective of the low-density lipoprotein receptor

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Importance of proprotein convertase subtilisin/kexin type 9 in the hormonal and dietary regulation of rat liver low-density lipoprotein receptors

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A new method for measurement of total plasma PCSK9: clinical applications

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Genetic and metabolic determinants of plasma PCSK9 levels

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Plasma levels of PCSK9 and phenotypic variability in familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Inhibition of PCSK9: a powerful weapon for achieving ideal LDL cholesterol levels

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of the Mediterranean diet with and without weight loss on surrogate markers of cholesterol homeostasis in men with the metabolic syndrome.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Association between plasma PCSK9 and gamma-glutamyl transferase levels in diabetic patients

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Association of serum proprotein convertase subtilisin/kexin type 9 with carotid intima media thickness in hypertensive subjects.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Proprotein convertase subtilisin-kexin type 9 is elevated in proteinuric subjects: relationship with lipoprotein response to antiproteinuric treatment

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Relationship of proprotein convertase subtilisin-kexin type 9 levels with resistin in lean and obese subjects

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Dyslipidaemia: 1-Year results from OSLER trial of anti-PCSK9 monoclonal antibody evolocumab.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of the proprotein convertase subtilisin/kexin 9 monoclonal antibody, AMG 145, in homozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Effect of a monoclonal antibody to PCSK9 on LDL cholesterol

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 is required for the disposal of non-acetylated intermediates of the nascent membrane protein BACE1.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 is not involved in the degradation of LDL receptors and BACE1 in the adult mouse brain

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Characterization of proprotein convertase subtilisin/kexin type 9 (PCSK9) trafficking reveals a novel lysosomal targeting mechanism via amyloid precursor-like protein 2 (APLP2).

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

No genetic association between PCSK9 polymorphisms and Alzheimer's disease and plasma cholesterol level in Japanese patients

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 reduces the protein levels of the LDL receptor in mouse brain during development and after ischemic stroke

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Circulating proprotein convertase subtilisin/kexin 9 (PCSK9) regulates VLDLR protein and triglyceride accumulation in visceral adipose tissue.

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Proprotein convertase subtilisin/kexin type 9 deficiency reduces melanoma metastasis in liver

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Regulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Annexin A2 is a natural extrahepatic inhibitor of the PCSK9-induced LDL receptor degradation

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

PCSK9 impedes hepatitis C virus infection in vitro and modulates liver CD81 expression

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration

1 reference

https://api.crossref.org/works/10.1007%2FS11883-014-0439-8

21 January 2018

Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Plasma lipoprotein-associated phospholipase A2 is inversely correlated with proprotein convertase subtilisin-kexin type 9

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Trial watch: PCSK9 antibody reduces LDL cholesterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

PCSK9 SNP rs11591147 is associated with low cholesterol levels but not with cognitive performance or noncardiovascular clinical events in an elderly population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Effects of n-6 PUFAs compared with SFAs on liver fat, lipoproteins, and inflammation in abdominal obesity: a randomized controlled trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A novel mutation in proprotein convertase subtilisin/kexin type 9 gene leads to familial hypercholesterolemia in a Chinese family.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Serum proprotein convertase subtilisin kexin type 9 is correlated directly with serum LDL cholesterol

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

[PCSK9, from gene to protein: a new actor involved in cholesterol homeostasis]

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Familial hypercholesterolemia: pathogenesis of a receptor disease

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic variants in PCSK9 in the Japanese population: rare genetic variants in PCSK9 might collectively contribute to plasma LDL cholesterol levels in the general population

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Circulating PCSK9 is a strong determinant of plasma triacylglycerols and total cholesterol in homozygous carriers of apolipoprotein ε2

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men.

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Endogenous estrogens lower plasma PCSK9 and LDL cholesterol but not Lp(a) or bile acid synthesis in women

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Genetic localization to chromosome 1p32 of the third locus for familial hypercholesterolemia in a Utah kindred

1 reference

https://pubmed.ncbi.nlm.nih.gov/25052769

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S11883-014-0439-8

1 reference

Europe PubMed Central

2 August 2017

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

2 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34430377&oldid=1835202572"